Repository logo
 
Publication

Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?

2020Journal article Open access
Simple item page
dc.contributor.authorSantos, PB
dc.contributor.authorPatel, H
dc.contributor.authorHenrique, R
dc.contributor.authorFélix, A
dc.date.accessioned2020-07-07T10:09:32Z
dc.date.available2020-07-07T10:09:32Z
dc.date.issued2020
dc.description.abstractProstate cancer (PCa) is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality. It emerges through the acquisition of genetic and epigenetic alterations. Epigenetic modifications include DNA methylation, histone modifications and microRNA deregulation. These generate heritable transformations in the expression of genes but do not change the DNA sequence. Alterations in DNA methylation (hypo and hypermethylation) are the most characterized in PCa. They lead to genomic instability and inadequate gene expression. Major and minor-specific modifications in chromatin recasting are involved in PCa, with signs suggesting a dysfunction of enzymes modified by histones. MicroRNA deregulation also contributes to the initiation of PCa, including involvement in androgen receptor signalization and apoptosis. The influence of inflammation on prostate tumor carcinogenesis is currently much better known. Recent discoveries about microbial species resident in the urinary tract suggest that these are the initiators of chronic inflammation, promoting prostate inflammatory atrophy and eventually leading to PCa. Complete characterization of the relationship between the urinary microbiome and prostatic chronic inflammation will be crucial to develop plans for the prevention of PCa. The prevalent nature of epigenetic and inflammatory alterations may provide potential biomarkers for PCa diagnosis, treatment decisions, evaluation of prognosis and posttreatment surveillance.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationWorld J Clin Oncol. 2020 Feb 24;11(2):43-52.pt_PT
dc.identifier.doi10.5306/wjco.v11.i2.43pt_PT
dc.identifier.issn2218-4333
dc.identifier.urihttp://hdl.handle.net/10400.10/2458
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBaishideng Publishing Grouppt_PT
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046922/pdf/WJCO-11-43.pdfpt_PT
dc.subjectProstatic neoplasmspt_PT
dc.subjectAntineoplastic agentspt_PT
dc.subjectEpigenomicspt_PT
dc.subjectBiomarkerspt_PT
dc.titleCan epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlacePleasanton, CApt_PT
oaire.citation.titleWorld journal of clinical oncologypt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
World J Clin Oncol. 2020.pdf
Size:
471.19 KB
Format:
Adobe Portable Document Format
Download

Collections

URO - Artigos publicados em revistas não indexadas